|8.87||-0.0300||-0.34%||Vol 100.79K||1Y Perf -34.87%|
|Apr 23rd, 2021 10:36 DELAYED|
|- -%||- -|
|Target Price||18.00||Analyst Rating||Strong Buy 1.00|
|Potential %||102.93||Finscreener Ranking||★★★★★ 69.24|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★★★ 70.93|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★★ 94.69|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Market Cap||254.27M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||4.37||Earnings Date||13th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th May 2021|
|Estimated EPS Next Report||0.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||640.05K|
|Avg. Monthly Volume||1.21M|
|Avg. Quarterly Volume||1.46M|
Co-Diagnostics Inc. (NASDAQ: CODX) stock closed at 8.9 per share at the end of the most recent trading day (a 2.18% change compared to the prior day closing price) with a volume of 690.46K shares and market capitalization of 254.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 39 people. Co-Diagnostics Inc. CEO is Dwight H Egan.
The one-year performance of Co-Diagnostics Inc. stock is -34.87%, while year-to-date (YTD) performance is -4.3%. CODX stock has a five-year performance of %. Its 52-week range is between 7.86 and 30.99, which gives CODX stock a 52-week price range ratio of 4.37%
Co-Diagnostics Inc. currently has a PE ratio of 6.20, a price-to-book (PB) ratio of 3.81, a price-to-sale (PS) ratio of 3.46, a price to cashflow ratio of 8.80, a PEG ratio of 2.32, a ROA of 115.35%, a ROC of 99.37% and a ROE of 123.87%. The company’s profit margin is 59.94%, its EBITDA margin is 52.90%, and its revenue ttm is $73.00 Million , which makes it $2.55 revenue per share.
Of the last four earnings reports from Co-Diagnostics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. Co-Diagnostics Inc.’s next earnings report date is 13th May 2021.
The consensus rating of Wall Street analysts for Co-Diagnostics Inc. is Strong Buy (1), with a target price of $18, which is +102.93% compared to the current price. The earnings rating for Co-Diagnostics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Co-Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Co-Diagnostics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.80, ATR14 : 1.15, CCI20 : -57.20, Chaikin Money Flow : -0.19, MACD : -1.60, Money Flow Index : 45.59, ROC : -3.99, RSI : 46.78, STOCH (14,3) : 45.20, STOCH RSI : 0.78, UO : 41.65, Williams %R : -54.80), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Co-Diagnostics Inc. in the last 12-months were: Dwight H Egan (Option Excercise at a value of $296 500), Dwight H Egan (Sold 172 396 shares of value $1 835 965 ), Eugene Durenard (Option Excercise at a value of $116 750), Eugene Durenard (Sold 120 500 shares of value $2 020 945 ), James Nelson (Sold 12 500 shares of value $126 631 ), Reed L. Benson (Option Excercise at a value of $110 000), Reed L. Benson (Sold 89 524 shares of value $940 002 ), Richard S. Serbin (Option Excercise at a value of $233 500), Richard S. Serbin (Sold 127 000 shares of value $2 100 650 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.